Author Archives: Kara Elam

Positive Results from Phase 3 Trial of Combo Therapy for Multiple Myeloma Presented at ASCO 2016

Researchers from Janssen Research & Development presented promising interim results from the Phase 3 MMY3004 (CASTOR) clinical trial, assessing the immunotherapy drug daratumumab (Darzalex) against standard of care in previously treated multiple myeloma patients, at the recent American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago. Specifically, the ongoing trial (NCT02136134) showed…

ICER Analyzes Cost and Value of Drugs Used to Treat Multiple Myeloma in New Report

The Institute for Clinical and Economic Review (ICER), an independent nonprofit based in Boston that analyzes the value of drugs and other medical services, has released a new report detailing the clinical effectiveness, long-term cost-effectiveness, and potential budget impact of treatments for multiple myeloma (MM). The report, “Treatment Options for Relapsed or Refractory…